Immune Activation Imaging for COVID-19
Trial Summary
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team to get a clear answer.
Research on similar imaging agents, like 18F-AzaFol, shows potential in visualizing activated macrophages (immune cells) in lung diseases, which could help identify COVID-19 patients at risk of severe complications. This suggests that [18F]F-AraG might also be useful in monitoring immune responses in COVID-19.
12345This treatment uses a novel imaging technique with 124I-iodo-DPA-713, which targets activated macrophages (immune cells involved in inflammation) to visualize the immune response in the lungs of COVID-19 patients. Unlike standard treatments that focus on directly combating the virus or reducing symptoms, this approach aims to provide detailed insights into the immune processes, potentially aiding in identifying patients at risk of severe disease progression.
12345Eligibility Criteria
This trial is for adults over 18 who've recently had COVID-19, with symptoms starting at least 14 days ago or a positive test if asymptomatic. They must have certain blood cell counts and organ function levels, not be pregnant or breastfeeding, and agree to use two forms of birth control if applicable.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants receive an intravenous microdose of [18F]F-AraG followed by whole-body PET-CT imaging
Optional Imaging Extension
Participants may receive a second optional [18F]F-AraG dose and PET-CT imaging
Follow-up
Participants are monitored for safety and effectiveness after imaging